Browsing by Author "Serin, İstemi"
Now showing items 1-7 of 7
-
DNA repair genes and chronic myeloid leukemia: ERCC2 (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (-1394) gene polymorphisms
Özdilli, Kürşat; Pehlivan, Mustafa; Serin, İstemi; Oğuz Savran, Fatma; Tomatır, Ayşe Gaye; Pehlivan, Sacide (Mattioli 1885, 2021)To the editor. Chronic myeloid leukemia (CML), which is characterized by the overproduction of mature cells in the granulocytic series, is included in the group of chronic myeloproliferative neoplasms.1 It is the first ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Otolog kök hücre transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) reaktivasyonu: Tek merkez deneyimi
Gemici, Aliihsan; Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Sadri, Sevil; Serin, İstemi; Erol, Vedat Buğra; Sargın, Fatma Deniz; Kaynar, Leylagül (Lösemi Lenfoma Miyelom Derneği, 2022)Amaç: Sitomegalovirüs (CMV) reaktivasyonu allojenik hematopoetik kök hücre transplantasyo- nu sırasında sık görülür. Hepatit B reaktivasyonu (HBV), akut hepatit ve fulminan karaciğer yet- mezliği veya sadece HBV DNA düzeyinde ... -
Quality of life assessment with EORTC QLQ in patients with hodgkin lymphoma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Sevindik, Ömür Gökmen (Ankara Hematology Oncology Association, 2022)Aim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 ... -
Quality of life assessment with EORTC QLQ in patients with multiple myeloma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Koç Erol, İklil Nur; Arslan, Zeynep Ece; Tay, Zekiye Nur; Tuncer, Elif Nur; Sevindik, Ömür Gökmen (Galenos Publishing House, 2022)Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
Sevindik, Ömür Gökmen; Mergen, Mahmut; Mergen, Sena; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Springer Science and Business Media Deutschland GmbH, 2022)Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. ...
